The US Food and Drug Administration (FDA) has issued 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites.
Sent on February 20 and made public in early March, the letters cite violations including claims implying compounded products are the same
The
Register for free to keep reading
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day